509093-76-9

Upstream product

• 509093-74-7 1-[(4-fluoro-3-nitrophenyl)methyl]piperidine 
• 42564-51-2 4-fluoro-3-nitrobenzaldehyde 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 20274-69-5 (4-fluoro-3-nitrophenyl)methanol 
• 509093-75-8 N₁-phenyl-4-piperidin-1-ylmethyl-benzene-1,2-diamine 
• 506-68-3 bromocyane 

Downstream Products

• 509093-72-5 N-(1-phenyl-5-piperidin-1-ylmethyl-1H-benzoimidazol-2-yl)-3-trifluoromethylbenzamide 
• 509093-77-0 N-(1-Phenyl-5-piperidin-1-ylmethyl-1H-benzoimidazol-2-yl)-3-nitro-benzamide 

Relevant academic research and scientific papers

Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4

In this Letter, we report the continued optimization of the N-acyl-2-aminobenzimidazole series, focusing in particular on the N-alkyl substituent and 5-position of the benzimidazole based on the binding mode and the early SAR. These efforts led to the discovery of 16, a highly potent, selective, and orally bioavailable inhibitor of IRAK-4.

Benzimidazole derivatives

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.